Psoriasis
Almirall relaunches psoriasis miniseries to highlight mental health impact
Almirall is seizing the occasion of World Psoriasis Day to underscore the profound impact of this skin condition on mental ...
Tremfya clears psoriasis in people of color, first study of its kind shows
The journey to improved treatments for psoriasis, a challenging skin condition, has been long and complex. Despite advances, some patient ...
Bimzelx, a potential blockbuster for psoriasis, clears FDA approval after resolving manufacturing issues
UCB’s long-awaited FDA approval for its psoriasis therapy, Bimzelx (bimekizumab), has finally arrived, ending a journey marked by manufacturing setbacks. ...
Evelo seeks new partner after microbiome platform fails to beat placebo
In a series of unfortunate turns, Evelo Biosciences, a biotech company backed by Flagship Ventures and that went public in ...
Dermavant plans to file Vtama for FDA approval after positive results in itchy skin condition
Dermavant is advancing in the race to develop nonsteroidal topical treatments for autoimmune skin conditions, building on its FDA approval ...
UCB’s psoriasis drug application overcomes manufacturing hurdle but hits another FDA delay
After facing delays related to manufacturing issues, UCB’s psoriasis medication, bimekizumab, is awaiting the next steps in its FDA review ...
Amgen Takes a Playful Approach with Otezla Advertisement Amid Growing Competition in the Psoriasis Market
Amgen, a major biotech company, has taken an innovative approach to connect with psoriasis patients by using humor in their ...
Skyrizi Beats Placebo in Psoriasis Phase 4 Study
Source – Abbvie On July 26, 2023 AbbVie announced the publication of results from the Phase IVĀ IMMpulse study in ...
Janssen rejoices at JNJ-2113A’s successful psoriasis study findings
Source – Johnson & Johnson On July 4, 2023, Janssen, a subsidiary of Johnson & Johnson announced positive initial results ...
BMS’ Sotyktu is approved for psoriasis usage by the NHS
Source: Bristol-Myers Squibb Just weeks after receiving approval in the UK, Bristol-Myers Squibb’s novel oral therapy for psoriasis, SotyKtu, has ...
